Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation

Survival Benefit of Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation: A Multicenter Retrospective Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05616377

Acronym

CLTBME

Enrollment

2000

Registered

2022-11-15

Start date

2022-11-20

Completion date

2024-11-20

Last updated

2022-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Metastases

Brief summary

The goal of this observational study is to learn about the survival benefit of local therapy combination with target therapy in lung cancer brain metastases with EGFR mutation. The main questions it aims to answer are: * Is local therapy performed before or after target therapy would provide survival benefit ? * What kind of local therapy combining with target therapy would provide survival benefit, neurosurgical resection or radiotherapy?

Interventions

OTHERSurgery or Radiotherapy

Participants who underwent target therapy and surgery or radiotherapy were divided into target therapy + local therapy group. Participants who underwent target therapy alone were divided into target therapy alone group

OTHERbefore or after target therapy

Participants who underwent surgery or radiotherapy before target therapy were divided into local therapy before target therapy group. Participants who underwent surgery or radiotherapy after target therapy were divided into local therapy after target therapy group.

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Evidence of pathological diagnosis of primary tumor. 2. Brain metastases confirmed by enhanced magnetic resonance imaging. 3. Gene test indicated that EGFR mutation. 4. Complete clinical information.

Exclusion criteria

1. If surgical treatment is accepted, the surgical treatment is not tumor resection, but ventricle puncture, biopsy and other non-tumor reducing surgery. 2. Patients with 2 or more types of tumors. 3. Incomplete clinical information.

Design outcomes

Primary

Measure	Time frame	Description
OS	From date of first follow-up until the date of documented death from any cause, assessed up to 120 months	Overall survival

Secondary

Measure	Time frame	Description
PFS	From date of first follow-up until the date of first documented progression, assessed up to 120 months	Progression-free survival

Contacts

Primary ContactLun Liang, PHD

lianglun@sysucc.org.cn18277186779

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026